Drugs / Tdap
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05827874 Background | Apr → Oct 2023 | — | Janssen Research & Development, LLC | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tdap | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05827874 ↗ |
| Route | Intramuscular | “Tdap will be administered as an IM injection.” NCT05827874 ↗ |